Search details
1.
High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.
Mol Cancer Res
; 19(9): 1510-1521, 2021 09.
Article
in English
| MEDLINE | ID: mdl-34039647
Results
1 -
1
de 1
1
Next >
>>